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Abstract
Chimeric antigen receptors (CARs) have been used to redirect the specificity of autologous T-cells 
against leukemia and lymphoma with promising clinical results.(1–3) Extending this approach to 
allogeneic T-cells is problematic as they carry a significant risk of graft-versus-host disease 
(GVHD).
Natural killer (NK) cells are highly cytotoxic effectors, killing their targets in a non-antigen 
specific manner without causing GVHD. Cord blood (CB) offers an attractive, allogeneic, off-the-
self source of NK cells for immunotherapy. We transduced CB-derived NK cells with a retroviral 
vector incorporating the genes for CAR-CD19, IL-15 and inducible caspase-9-based suicide gene 
(iC9), and demonstrated efficient killing of CD19-expressing cell lines and primary leukemia cells 
in vitro, with dramatic prolongation of survival in a xenograft Raji lymphoma murine model. 
IL-15 production by the transduced CB-NK cells critically improved their function. Moreover, 
iC9/CAR.19/IL-15 CB-NK cells were readily eliminated upon pharmacologic activation of the iC9 
suicide gene. In conclusion, we have developed a novel approach to immunotherapy using 
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engineered CB-derived NK cells which are easy to produce, exhibit striking efficacy and 
incorporate safety measures to limit toxicity. This approach should greatly improve the logistics of 
delivering this therapy to large numbers of patients, a major limitation to current CAR-T cell 
therapies.
INTRODUCTION
Chimeric antigen receptors (CARs) that redirect the specificity of autologous T-cells against 
lymphoid malignancies have produced striking clinical results.(1–6) Nonetheless, CAR-
modified T-cells have a number of limitations. The generation of an autologous product for 
each individual patient is logistically cumbersome and restrictive for widespread clinical 
use. The manufacturing of CAR T-cells often takes several weeks, making it impractical for 
patients with rapidly advancing disease. Furthermore, it is not always possible to generate 
clinically relevant doses of CAR T-cells from heavily pre-treated, often lymphopenic 
patients. A previously collected allogeneic product could overcome these limitations; 
however, allogeneic T-cells (even if HLA-matched) carry a risk of graft-versus-host disease 
(GVHD),(7) mediated through their native αβ T-cell receptor.
Natural killer (NK) cells provide an attractive alternative to T-cells for CAR engineering. 
NK cells do not cause GVHD,(8, 9) and thus open opportunities to produce an off-the-shelf 
product for immediate clinical use. Moreover, as engineered NK cells should also retain 
their full array of native receptors, they have the potential to exert cytotoxicity(10) through 
mechanisms other than that dictated by the specificity of the CAR, which in principle could 
reduce the risk of relapse mediated by loss of CAR-targeted antigen, as reported for CAR-T 
cell therapy.(11)
Functional NK cells can be derived from several sources.(9, 12, 13) Autologous NK cells 
can be reproducibly generated in vitro, but have limited activity against autologous tumors,
(14, 15) which may not be overcome by CAR engineering. Cord blood (CB) is a readily 
available source of allogeneic NK cells with clear advantages. CB is available as an off-the-
shelf frozen product, an advantage that has been bolstered by methods to generate large 
numbers of highly functional NK cells from frozen CB units ex vivo.(16) The generation of 
CAR-transduced NK cells from frozen CB units stored in large global CB bank inventories 
holds promise for widespread scalability that cannot be replicated with individual adult 
donors who require screening and leukapheresis. However, a major disadvantage of NK cells 
is their lack of persistence after adoptive transfer in the absence of cytokine support.(17) 
Finally, CAR-engineered NK cells may also exert potentially serious toxicity, such as 
cytokine release syndrome (CRS) or off-tumor/on-target toxicity, as reported with CAR T-
cells.(18)
Here, we present a novel approach to the generation of CAR-CD19+ NK cells that we 
believe addresses the limitations described above. We genetically modified NK cells with a 
retroviral vector (iC9/CAR.19/IL15) that (i) incorporates the gene for CAR.19 to redirect 
their specificity; (ii) ectopically produces IL-15, to support their survival and proliferation,
(19, 20) and (iii) expresses a suicide gene, inducible caspase-9 (iC9), that can be 
pharmacologically activated to eliminate transduced cells.(21) We investigated whether these 
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genetic modifications would enable CB NK cells to persist in sufficient numbers to 
effectively kill B-cell malignancies.
METHODS
Cell lines
K562-based feeder cells expressing membrane-bound IL-21 and CD137-ligand (Clone 
9.mbIL21)(16) were generously provided by Laurence Cooper, MD Anderson Cancer 
Center (MDACC). Clone 9.mbIL21 cells co-express CD64/FcγRI, CD86/B7-2, CD137L/
4-1BBL, truncated CD19, and membrane-bound IL-21 was recently reported to promote 
peripheral blood and CB NK cell expansion (16, 22). Raji (Burkitt lymphoma cell line) and 
K562 (erythroleukemia cell line) were purchased from ATCC (Manassa, VA).
Patient details
Primary CLL cells from 6 patients were used for in vitro studies of NK-CAR cytotoxicity. 
Patient characteristics are summarized in Supplementary Table 1.
Plasmid construction and retrovirus production
The retroviral vectors encoding iC9.CAR19.CD28-zeta-2A-IL-15 and firefly luciferase 
(FFLuc) have been described.(19, 23) Transient retroviral supernatants were produced as 
previously described.(23)
Generation of CAR-modified NK cells
CB units for research were provided by the MDACC CB Bank and peripheral blood 
mononuclear cells (PBMCs) were collected from CLL patients following informed consent, 
under IRB-approved protocols. CB and PBMCs were isolated by a density-gradient 
technique (Ficoll-Histopaque; Sigma). CD56+ NK cells, purified with an NK isolation kit 
(Miltenyi Biotec, Inc., San Diego, CA), were stimulated with irradiated (100 Gy) Clone 9 
(2:1 feeder cell:NK ratio) and recombinant human IL-2 (Proleukin, 200 U/mL; Chiron, 
Emeryville, CA) in complete Serum-free Stem Cell Growth Medium (SCGM) (CellGenix 
GmbH, Freiburg, Germany) on day 0. Activated NK cells were transduced with retroviral 
supernatants on day +4 in human fibronectin-coated plates (Clontech Laboratories, Inc., 
Mountain View, CA). Five days later (day +9), NK cells were stimulated again with 
irradiated Clone 9 and IL-2. On day +14, CAR-transduced NK cells were harvested for use.
CAR expression and immunophenotype of transduced cells
Transduced CB-NK cells were stained with Alexa-Fluor647 affinity-purified F(ab′)2 
fragment goat anti-human IgG (H+L) antibody (CAR Ab) (Jackson ImmunoResearch, West 
Grove, PA) for CAR expression (see supplementary material for details of antibodies used to 
phenotype NK cells).
IL-15 cytokine secretion
IL-15 production was measured with the human IL-15 Quantikine ELISA kit (R&D) 
following the manufacturer’s instructions.
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On day 14 of culture, control non-transduced (NT) and CAR-transduced CB-NK cells 
(0.25×106 cells/well) were cocultured for 5 hours in 96-well plates with purified CLL cells, 
Raji cells, or K562 targets (positive control) at an effector: tumor cell ratio (E:T) of 5:1. 
CD107a degranulation and intracellular cytokine production were measured as previously 
described.(14) (See supplementary material for assay details).
NK cell proliferation and cytotoxicity assays
To evaluate for autonomous NK cell growth, we maintained control NT and iC9/CAR.19/
IL15+ NK cells in SCGM without stimulation or addition of exogenous cytokines. Cells 
were cultured for 42 days, and counted using trypan blue exclusion every 3 days.
To assess cytotoxicity, CAR-transduced and NT-NK cells were cocultured with 51Cr-labeled 
CLL, Raji and K562 targets (positive control) at multiple E:T ratios; cytotoxicity was 
measured by 51Cr-release as previously described,(14) the findings are reported as specific 
lysis relative to K562 targets.(24) For HLA-blocking experiments, the anti-HLA-ABC clone 
W6/32 (Biolegend) was used.
Confocal microscopy and measurement of MTOC polarization
Conjugates were imaged by sequential scanning with a Leica TCS SP8 laser scanning 
confocal microscope as previously described.(25) Details are included in the supplementary 
material.
Xenogeneic lymphoma models
To assess the persistence and anti-tumor effect of CAR-transduced CB-NK cells in vivo, we 
used a NOD/SCID IL-2Rγnull (NSG) xenograft model, with the aggressive NK-resistant 
Raji cell line. Mouse experiments were performed in accordance with NIH 
recommendations under protocols approved by the Institutional Animal Care and Use 
Committee.
Anti-tumor effect of CAR-transduced CB-NK cells
NSG mice (10–12 weeks old; Jackson Laboratories, ME) were irradiated with 300 cGy and 
inoculated intravenously (i.v.) with FFLuc-labeled Raji cells (2 × 105) on day 0. Where 
indicated, 10×106 fresh, aAPC-expanded NT or CAR-transduced CB-NK cells were injected 
through the tail vein on days 0 and 7. Mice were subjected to weekly bioluminescence 
imaging (BLI; Xenogen-IVIS 200 Imaging system; Caliper, Waltham, MA). Signal 
quantitation in photons/second (p/s) was performed by determining the photon flux rate 
within standardized regions of interest using Living Image software (Caliper).(16) In 
selected experiments, mice received NT-NK cells or CB-NK cells transduced with CAR.19 
(lacking IL-15 in the construct) plus low dose recombinant human IL-15 (Miltenyi Biotech) 
intra-peritoneally (i.p.) at the dose of 0.5 μg/mouse (i.e. 2.500 Units/mouse) on the day of 
NK cell infusion and thereafter every 2–3 days for 2 weeks, following established protocols.
(26).
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Trafficking, persistence and expansion of transduced vs. NT-NK cells were measured by 
flow cytometry.
Activation of suicide gene in vitro and validation in vivo
The small molecule dimerizer AP1903 (10nM), generously provided by Bellicum 
Pharmaceuticals, Inc. (Houston, Texas), was added to NK cell cultures for 4 hours. The 
elimination of transduced cells was evaluated by Annexin-V/7-AAD staining. The efficacy 
of the suicide gene was tested in vivo by treating tumor-bearing mice that had received iC9/
CAR.19/IL15+ NK cells with two doses of AP1903 (50 μg each) intraperitoneally (i.p.), 2 
days apart.(19)
Karyotyping and single nucleotide polymorphism (SNP) microarray analysis
Standard karyotyping and SNP analysis were performed in the MDACC Cytogenetics 
Laboratory (See supplementary material for details).
Pathologic analysis
Mice were euthanized and necropsied 10 months after the first treatment, at the age of 13 
months. Blood samples were collected immediately after euthanasia and analyzed with 
Advia 120. Formalin-fixed tissues were embedded in paraffin blocks, cut into 4-μm thick 
sections, H&E-stained and examined microscopically by a trained pathologist.
Statistical analysis
Student’s t test was used to compare quantitative differences (mean ± SD) between samples; 
p values were two sided and p<0.05 was considered significant. For all bioluminescence 
experiments, intensity signals were summarized as means±SD at baseline and at multiple 
subsequent timepoints for each group of mice.(16) Probabilities of survival were calculated 
using the Kaplan Meier method.
RESULTS
CB-NK cells can be stably transduced with a retroviral vector to express iC9/CAR.CD19/
IL-15
Two million NK cells were isolated from banked CB units and cultured with Clone 9 and 
IL-2 for 14 days (non-transduced [NT] control) or transduced on day +4 with a retroviral 
vector expressing iC9/CAR.19/IL15 and cultured for an additional 10 days (see Methods). 
NK cell viability on day 4 after transduction was ≥95% in all cases. The median CAR-NK 
transduction efficiency on day 14 of culture was 66.6% (range, 47.8–87.4%; n=18) 
(Supplementary Fig. 1A). Table 1 summarizes data on fold-expansion and absolute CAR-
NK counts from 5 different CB units. After 14 days of culture, the median NK cell 
expansion was 2222-fold (range 564–7370).
We studied the stability of CAR expression over time by culturing CAR-transduced CB-NK 
cells from 6 different CB units for a total of 7 weeks. CAR expression remained stable over 
this interval, as determined by flow cytometry every 10–14 days. In addition, there was no 
significant difference in the expression level of CAR when NK cells were transduced with 
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iC9/CAR.19/IL-15 or CAR19 (lacking IL-15). Representative FACS plots and a summary of 
the data are presented in Supplementary Fig 1B–C.
Transduction with iC9/CAR.19/IL-15 enhances CB-NK cytotoxicity against CD19+ tumor 
targets in vitro
We tested whether engineering CB-NK cells to express iC9/CAR.19/IL15 enhanced their 
cytotoxicity against CD19-expressing tumors compared to expanded, non-transduced (NT) 
CB-NK cells. iC9/CAR.19/IL15 CB-NK cells and NT CB-NK cells cultured for 14 days 
were co-incubated with Raji (n=18) (Fig 1A) or primary CLL cells (n=6) (Fig 1B) at 
different E:T ratios and their cytotoxicity was tested using a standard 51Cr-release assay. 
Across all E:T ratio, CAR-transduced CB-NK cells exerted superior killing of Raji and CLL 
cells compared to NT-NK cells. CAR-transduced NK cells were equally efficient as NT-NK 
cells in killing K562 targets (Fig 1A,B), indicating that the enhanced killing of CD19 targets 
by the transduced cells is mediated by the CAR receptor and not related to a non-specific 
enhancement in NK cytotoxicity.
To confirm that the enhanced cytotoxic activity against CD19 targets is derived from the 
iC9/CAR.19/IL15-expressing fraction of the product, we measured CD107a degranulation 
and IFN-γ and TNF-α response to Raji and CLL targets (n=8). As shown in Fig 1C, the 
CAR-positive NK cells were the main source of IFN-γ, TNF-α and CD107a in response to 
CD19+ targets, compared to the CAR-negative fraction, while the CAR-positive and CAR-
negative fractions showed similar effector function against K562 cells.
CB-derived iC9/CAR.19/IL15-transduced NK cells have superior cytotoxicity against 
primary CLL targets, compared to CLL patient-derived NK cells transduced with the same 
vector
We generated both NT and iC9/CAR.19/IL15-transduced NK cells from 2 CLL patients 
using the methodology described above and tested their ability to lyse autologous CLL cells 
in 3 independent experiments. We also compared their cytotoxicity with those of CB-derived 
iC9/CAR.19/IL15-transduced and NT-NK cells. Expanded NT-NK cells from CLL patients 
and CB were equally poorly cytotoxic against CLL targets (Supplementary Fig 2A). 
However, whereas CAR-transduced CB-NK cells could efficiently kill CLL cells, expression 
of the same vector by NK cells from patients only modestly increased their cytotoxicity 
against autologous CLL targets, suggesting that transduced NK cells from CLL patients will 
be less effective immunotherapy than healthy CAR-transduced CB cells. To investigate 
whether an inhibitory effect of KIR/self-HLA interaction could have impaired the 
cytotoxicity of patient-derived CAR-NK cells against autologous CLL cells, we repeated the 
experiments in the presence or absence of HLA class-I blocking (Supplementary Fig 2B). 
This intervention only partially improved the cytotoxicity of patient-derived CAR-
transduced NK cells against autologous targets. CLL cells express high levels of HLA-E 
(Supplementary Figure 2C), the ligand for the inhibitory receptor NKG2A. Thus, to 
determine if an inhibitory effect of NKG2A/HLA-E interaction could influence patient-
derived CAR-NK killing of autologous CLL cells, we repeated the experiments in the 
presence or absence of an NKG2A blocking antibody (clone Z199, Beckman Coulter). As 
shown in Supplementary Figure 2E, NKG2A blocking significantly improved the ability of 
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both NT-NK and CAR.19-transduced NK cells to recognize and kill primary CLL cells, 
without significantly influencing their cytotoxicity against K562 cells (Supplementary 
Figure 2D). Taken together, these data suggest that multiple mechanisms likely contribute to 
the relative inability of CAR-transduced patient-derived NK cells to kill autologous targets.
iC9/CAR.19/IL15-transduced CB-NK cells form a stronger immunologic synapse with CLL 
targets compared to CB-NK cells transduced with CAR.CD19 (without IL-15) or patient-
derived iC9/CAR.19/IL15-transduced NK cells
To gain insight into the specific mechanisms by which iC9/CAR.19/IL15-transduced CB-
NK cells mediate superior cytotoxicity and the contribution of IL-15 to this effect, we 
performed qualitative and quantitative assessments of immunologic synapse formation in 
human NK cells. We first asked whether CAR molecules accumulate at the immunologic 
synapse (IS) between iC9/CAR.19/IL15-transduced CB-NK cells and CLL targets and 
whether this recruitment was CD19 antigen-specific. Using confocal microscopy, we 
observed significantly higher accumulation of CAR molecules at the IS formed between 
CAR.19/IL15 CB-NK cells and CLL targets (Fig 2A–C) compared to the diffuse presence of 
CARs at the IS with K562 targets (Fig 2B,C), indicating that CAR molecules participate in 
IS formation in a CD19-dependent manner.
Increased polarization of the microtubule-organizing center (MTOC) is an essential step in 
the final stages of NK cell-mediated cytotoxicity and exocytosis of lytic granules at the IS.
(27) Thus, we used confocal microscopy to assess the MTOC polarization of NT CB-NK 
cells, iC9/CAR.19/IL15+ CB-NK, iC9/CAR.19/IL15+ CLL patient-derived NK cells and 
CAR.19-transduced CB-NK (lacking IL-15) in experiments with CLL targets. MTOC 
polarization was quantified by measuring the distance between the pericentrin-defined 
MTOC to the IS for at least 15 conjugates, including all four groups of NK cells and CLL 
targets. MTOC polarization against K562 targets was used as control as NK cells form a 
“natural” synapse with K562 targets through multiple activating receptors on their surface. 
As shown in Fig 2C and Supplementary Fig. 3, MTOC was significantly closer to the IS in 
iC9/CAR.19/IL15-transduced CB-NK cells compared to any of the remaining groups (Fig 
2C, left panel). CLL patient-derived iC9/CAR.19/IL15 NK cells did show improved 
polarization compared to NT-CB NK cells, but this gain was still significantly less than that 
seen with CB-NK cells transduced with iC9/CAR.19/IL15. No differences in MTOC 
polarization were observed among the NK cell groups in the presence of a non-CD19-
presenting K562 target (Fig 2C, right panel). These findings provide a mechanistic basis for 
the enhanced antitumor activity of iC9/CAR.19/IL15-transduced CB-NK cells; namely, 
engagement of CARs on transduced NK cells with CD19 on target cells results in increased 
polarization of the MTOC, and superior killing.
IL-15 by iC9/CAR.19/IL15+ CB-NK cells is produced predominantly in response to CD19+ 
targets and does not induce NK cell anergy
NT CB-NK and iC9/CAR.19/IL15+ CB-NK lymphocytes expanded for 14 days were 
cultured with or without CLL cells, and IL-15 release was measured at 24, 48 and 72 hours. 
IL-15 was undetectable in supernatants collected from NT CB-NK cells cultured alone or 
with CLL targets. By contrast, iC9/CAR.19/IL15+ CB-NK cells produced small amounts of 
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IL-15 in the absence of antigen stimulation (mean 15.05 pg/mL/106 cells, range 6.2–23.47), 
which significantly increased with antigen stimulation (mean 27.61 pg/mL/106 cells, range 
15.82–38.18) (Fig. 3A), in keeping with enhanced proliferation of iC9/CAR.19/IL-15+ CB 
NK cells in response to CLL cells in culture (Supplementary Fig. 4).
To investigate the potential of IL-15 to induce NK anergy, we comprehensively characterized 
the NK cell phenotype, including expression of activating and inhibitory receptors, 
exhaustion markers, chemokine receptors and transcription factors on expanded NK 
products by multiparameter flow cytometry. The heatmap in Fig 3B summarizes the average 
expression levels of markers from 3 independent CB-NK expansion and transduction 
experiments. Ex vivo expansion drove the maturation of both NT-NK and iC9/CAR.19/
IL15+ as evidenced by expression of CD16 and KIRs, (Fig. 3B and Supplementary Fig. 5) 
with no selectivity in the subsets of NK cell transduced with the CAR vector. iC9/CAR.19/
IL15+ CB-NK cells expanded for 2 weeks showed no signs of exhaustion, such as 
downregulation of eomesodermin and T-bet,(28), or upregulation of KLRG1, and in fact 
exhibited a phenotype similar to that of NT-NK cells. Moreover, in contrast to a previous 
report in murine NK cells that sustained stimulation with IL-15/IL-15R-α complexes 
induces dysfunction,(29) human iC9/CAR.19/IL15-transduced CB-NK cells proliferated as 
efficiently as NT CB-NK cells and followed a similar kinetic of in vitro expansion (Fig. 3C).
iC9/CAR.19/IL15-tranduced CB-NK cells exert enhanced anti-tumor activity in vivo
We used our Raji xenograft model to study the in vivo antitumor activity of iC9/CAR.19/
IL15-transduced CB-NK cells and the contribution of IL-15 to this effect. Mice received one 
i.v infusion (10×106/mouse) of control NT CB-NK cells, iC9/CAR.19/IL15-transduced CB-
NK cells or CAR.19 CB-NK cells lacking IL-15 (5 mice per group). Tumor growth was 
monitored by measuring changes in tumor bioluminescence over time. Tumor 
bioluminescence increased rapidly in mice treated with control NT CB-NK cells (Fig. 
4A,B). By contrast, infusion of either CAR.19+ or iC9/CAR.19/IL15+ CB-NK cells led to 
improved tumor control and significant prolongation of survival compared to NT CB-NK or 
CAR.19 CB-NK cells lacking IL-15 (and p=0.001 and p=0.044, respectively) (Fig. 4C). 
Notably, iC9/CAR.19/IL15+ CB-NK cells controlled tumor expansion (Fig. 4A) and 
prolonged survival (Fig. 4C) better than the CB-NK cells transduced with CAR.CD19 
without IL-15 (p=0.044), underscoring the vital contribution of IL-15 to enhanced antitumor 
activity. We also asked if intraperitoneal administration of low doses of recombinant human 
IL-15 could support the survival potential and anti-tumor efficacy of CAR.19 CB-NK cells 
(lacking IL15 in the construct). A dose of 0.5 μg/mouse (i.e. 2.500 Units/mouse) 
administered on the day of NK cell infusion and every 2–3 days thereafter resulted in 
significant expansion of CAR.19 NK cells and control of tumor progression (Supplementary 
Fig 6A–C); however, it was associated with significant toxicity and early mortality 
treatment-related mortality (Supplementary Fig 6D).
We next asked if increasing the dose of CB-NK cells could enhance anti-tumor activity by 
administering two i.v infusions (10×106 cells each, 5–7 days apart) of control NT or iC9/
CAR.19/IL15+ NK cells (5 mice per group). None of the mice receiving iC9/CAR.19/IL15+ 
CB-NK cells died of lymphoma (Fig. 4D). However, 3 mice died on days 11, 14 and 16 after 
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infusion of the cells from complications related to the release of inflammatory cytokines, 
including high levels of TNF-α (median 999.2 pg/mL), IL-1β (median 1271.4 pg/mL) and 
IL-18 (5570 pg/mL) detected in serum at the time of death. These data indicate that activated 
NK cells transduced with iC9/CAR.19/IL15 may also cause CRS similar to that of CAR T-
cells, with the potential to cause toxicity in humans.
IL-15 enhances the proliferation, persistence and homing of CAR.CD19-transduced CB-NK 
cells in a xenograft NSG mouse model of Raji lymphoma
To examine the contribution of IL-15 to the proliferation, persistence and homing of CAR-
NK, NSG mice engrafted with Raji lymphoma were treated with two i.v infusions (10×106 
cells each, 5–7 days apart) of NT CB-NK cells (control), CB-NK cells transduced with iC9/
CAR.19/IL15 or CAR.19 (lacking IL-15) as described in Methods (5 mice per group). On 
day +21 post-NK infusion, mice were sacrificed. High frequencies of CAR-expressing NK 
cell were identified in blood, bone marrow, liver and spleen of mice treated with iC9/CAR.
19/IL15 (Fig. 4E), indicating proliferation and successful homing of CAR-NK cells to sites 
of disease. Notably, there was no evidence of human CD19+ cells in any of the organs 
examined, consistent with efficient control of tumor by the iC9/CAR.19/IL15 CB-NK cells. 
By contrast, in mice treated with either CAR.19 CB-NK cells (lacking IL15) or NT CB-NK 
cells, proliferation or homing to sites of disease was more limited. Furthermore, CD19+ 
tumor cells were detected at high frequencies in blood and organs of the mice, suggesting 
that CAR.19 CB-NK cells lacking IL-15 are capable of controling the tumor for only a short 
period of time. Moreover, in mice receiving two infusions of iC9/CAR.19/IL15+ CB-NK 
cells, the cells expanded over time and could be detected up to 68 days post infusion, after 
which their numbers receded (Fig. 4F). These data indicate that IL-15 in the CAR construct 
endows CB-NK cells with the capacity to proliferate and persist in vivo in an antigen-driven 
manner.
iC9/CAR.19/IL15-transduced CB-NK cells do not show signs of dysregulated growth either 
in vitro or in vivo
To investigate the possibility that the IL-15 gene in the vector may result in autonomous or 
dysregulated growth of transduced CB-NK cells, we cultured iC9/CAR.19/IL15-transduced 
CB-NK cells in media without the addition of exogenous IL-2 or clone 9.mbIL21 for 42 
days (n=5). Cultured iC9/CAR.19/IL15-transduced CB-NK cells did not show any signs of 
abnormal growth over 6 weeks (Fig 5A), after which the cells stopped expanding. 
Karyotyping and SNP microarray analyses of CAR-transduced NK cells after up to 22 
weeks of culture (n=7) did not reveal any chromosomal alterations or evidence of genetic 
instability (data not shown).
Nine mice treated with CB-NK cells transduced with iC9/CAR.19/IL15 (n=5) or CAR.CD19 
(lacking IL-15) (n=4) were followed for at least 10 months and then sacrificed. The 
hematologic parameters were within normal ranges (Supplementary Table 2), with no 
evidence of lymphocytic leukemia in either treatment group (Fig 5B).
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iC9/CAR.19/IL15+ CB-NK cells are eliminated by activation of the suicide gene with a small-
molecule dimerizer
To counteract excessive toxicity mediated by the release of inflammatory cytokines by 
transduced CB-NK cells, we incorporated a suicide gene (iC9) into our construct.(21) The 
addition of as little as 10 nM of the small molecule dimerizer AP1903 to cultures of iC9/
CAR.19/IL15-transduced CB-NK cells induced apoptosis/necrosis of transduced NK cells 
within 4 hours but had no effect on the viability of NT CB-NK cells (Fig. 6A–B). The 
suicide gene was also effective in vivo. Mice engrafted with Raji tumor received iC9/CAR.
19/IL15-transduced CB-NK cells. Mice were then either treated with the dimerizer or not 
(n=5 mice per group) and were sacrificed 3 days later. Administration of the small-molecule 
dimerizer resulted in a striking reduction in iC9/CAR.19/IL15-transduced CB-NK cells in 
the blood and tissues of the treated mice (Fig 6C).
DISCUSSION
We have developed a novel approach to engineering NK cells with potent antitumor activity 
by transducing CB-derived NK cells with a retroviral vector encoding a CAR against CD19, 
IL-15 (a cytokine crucial for NK cell persistence), and the inducible caspase-9 suicide gene. 
NK cells transduced with this vector form strong immunologic synapses with CD19-positive 
targets and effectively kill CD19-expressing leukemia/lymphoma cell lines as well as 
primary CLL cells. Moreover, when the iC9/CAR.19/IL15-transduced CB-NK cells were 
infused into an NSG mouse model of Raji lymphoma, they proliferated rapidly in vivo and 
homed to sites of disease, where they mediated potent antitumor responses.
We chose CD19 as the target for our studies, as proof-of-principle, based on the striking 
clinical efficacy shown by CAR.CD19+ T-cells against B-lineage cancers(1–6). The 
signaling domain of our construct contains CD28 and CD3ζ. CD3ζ is crucial for both T and 
NK cell signaling and activation.(30, 31) While CD28 is well recognized as an important 
costimulatory molecule for T cell activation,(32) its role in NK cell activation is less clear; 
however, human fetal NK cells and a number of NK cell lines express CD28 and can kill 
CD80/CD86-expressing tumor targets, supporting a role for CD28 in the activation of NK 
cells.(33–35) Further, CD28 ligation in NK cells enhances NK cell killing of its target by 
phosphorylating ERK2.(27) In our study, NK cells transduced with a CAR incorporating 
CD28 showed marked antitumor activity, both in vitro and in vivo, although other 
costimulatory domains, such as 4-1BB,(17) may improve results further.
CAR-NK cells also exert cytotoxicity that is non-CAR.CD19-mediated, as demonstrated by 
the modest killing of tumor targets by non-transduced NK cells. This could represent an 
advantage for NK cells over T-cells in CAR-driven immunotherapy, as the intrinsic capacity 
of NK cells to recognize and target tumor cells remains intact, making disease escape 
through downregulation of the CAR target antigen less likely than it is with CAR-T cells. 
One could potentially exploit this property by selecting donors for NK-CAR production 
based on KIR-ligand mismatch with the recipient, or haplotype B KIR gene content, as 
shown in the setting of stem cell transplantation.(8, 13, 36–38) Using readily accessible CB 
units and GMP-compliant procedures for robust expansion (19), it is feasible to generate 
multiple clinical doses of CAR-NK cells from a single CB unit (Table 1).
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Mature NK cells have a short lifespan with poor in vivo persistence both in humans and in 
mice(39, 40). Although recent data support the existence of long-lived memory NK cells in 
mice (41, 42) and possibly in humans(43–45), the absence of a reliable and stable marker (or 
set of markers) to define memory NK cells hinders their selection for immunotherapy. This 
poses a major limitation on their use for adoptive therapy, as in vivo persistence of effector 
cells are crucial for sustained clinical responses.(46) We therefore incorporated in our 
construct the gene encoding IL-15, a cytokine that drives NK cell expansion and persistence.
(19, 20, 47) This modification led to ectopic production of IL-15, which was predominantly 
antigen-driven, and to more robust activation of NK cells with enhanced in vivo 
proliferation, persistence and anti-tumor activity than that seen with CAR.19-transduced NK 
cells lacking IL-15. Although the latter could mediate an antitumor response, the effect was 
only transient, further emphasizing the importance of in vivo persistence of CAR-expressing 
NK cells for effective and durable antitumor immunity. We also examined if exogenous 
administration of IL-15 could support the in vivo proliferation and anti-tumor activity of 
CAR19-transduced NK cells, thus, overcoming the requirement to include IL-15 in the 
construct. However, IL-15, even when administered at a low dose of 0.5 μg/mouse every 2–3 
days(26) was associated with significant toxicity when administered in combination with 
CAR.CD19-transduced CB-NK cells (but not non-transduced NK cells), supporting our 
strategy to include IL-15 in the construct. It is conceivable that ectopic IL-15 production 
could lead to abnormal NK-cell proliferation or leukemia transformation.(48) In the present 
study only picogram quantities of IL15 were produced by our CAR-transduced CB-NK 
cells, without evidence of autonomous growth in vitro or leukemic transformation in vivo.
Severe toxicity, including on-target/off-tumor effects and CRS is a major clinical limitation 
of CAR-T cell therapy.(49) These concerns may also be relevant to CAR-NK cells. Human 
NK cells predominantly produce IFN-γ, IL-3 and GM-CSF (50), which may result in a 
different pattern and kinetic of CRS. In our study infusion of a higher number of iC9/CAR.
19/IL15-transduced CB-NK cells was associated with a systemic inflammatory response and 
toxic death in a number of mice. To counteract these potential toxicities, we equipped CAR-
modified NK cells with an inducible suicide gene(21) and showed that pharmacologic 
activation of this molecule could rapidly and efficiently eliminate the gene-modified NK 
cells.
In conclusion, we have developed a novel approach to immunotherapy using engineered CB-
derived NK cells. The iC9/CAR.19/IL15-transduced CB-NK cells are relatively easy to 
produce, show striking efficacy both in vitro and in vivo, and incorporate safety measures 
that are designed to limit toxicity. Clinical trials of these CAR-NK cells will begin shortly at 
our center.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Anti-tumor function of CB-NK cells transduced with the iC9/CAR.19/IL15 vector
Panels A and B summarize the cytotoxic activity of iC9/CAR.19/IL15-transduced CB-NK 
cells (CAR, solid lines) vs. NT CB-NK cells (broken lines), as measured by 51Cr release 
assay, against Raji (n=18) (A) and primary CLL cells (n=6) (B). CAR transduced NK cell 
kill CD19 expressing targets more efficiently than non-transduced (NT) ex vivo expanded 
and activated NK cells (p<0.001, all comparisons). CAR-transduced NK cells (solid blue 
line) were equally efficient as NT NK cells (broken blue line) in killing K562 targets. Data 
are presented as specific lysis relative to K562 targets(20) to correct for inter-donor 
variability in killing. (C) Cytokine production and CD107a degranulation by flow cytometry 
in gated CAR positive vs. CAR negative NK cells in response to different stimuli in 8 
independent experiments, showing that CAR transduction of CB-NK cells significantly 
increased their cytokine effector response (IFN-γ and TNF-α production) and CD107a 
degranulation to the CD19-expressing Raji cell line and primary CLL cells. The effector 
function of both iC9/CAR.19/IL15-transduced CB-NK-CAR and non-transduced NK cells 
against K562 was similar.
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Fig. 2. Assessments of immunologic synapse formation and function in human iC9/CAR.19/IL15-
transduced CB-NK cells
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(A) Confocal microscopy showing representative synapse images of CB-NK cells 
(transduced with iC9/CAR.19/IL15) conjugated to primary CLL cells. Conjugates were 
stained with anti-perforin (green), phalloidin-F-actin (red) and anti-CD19-CAR (yellow). 
Note formation of immunological synapse (black arrow; left panels). (B- top panel) 
Confocal representative images (original magnification ×100) demonstrating that CD19-
specific CAR on NK cells preferentially accumulates at the CLL (target) cell synapse and 
not at the K562 (non-target) cell synapse. Cells were imaged in Z stacks covering the entire 
volume of the immunological synapse. Imaging was performed on a Leica TCS SP8 
confocal microscope using a 100X oil objective. Images were acquired with Imaris software 
(Bitplane). Transmitted light (TL) overlay, single-color anti–CD19 CAR (blue), anti-perforin 
(red) and an overlay of all stains are shown. (B- bottom panel) summarizes data on the 
accumulation of CD19-specific CARs at the immunologic synapse between CB-NK cells 
transduced with iC9/CAR.19/IL15 vector with CLL cells (CD19 positive) vs. K562 targets 
(CD19 negative). *p= 0.02. There was significantly more accumulation of CD19-specific 
CARs at the immunologic synapse with CLL cells compared to K562 targets. (C) iC9/CAR.
19/IL15-transduced CB NK cells, CAR.19-transduced CB NK cells (without IL-15) and 
CLL patient-derived NK cells transduced with iC9/CAR.19/IL15 were assessed and 
compared with non-transduced NK cells for their ability to polarize lytic granules and 
MTOC to CLL targets (left panel) vs. K562 cells (right) (measured by distance from the 
MTOC to the immune synapse). Results from two independent experiments are shown; each 
data point represents a single immunologic synapse. Cells were imaged as a Z stack on a 
Leica TCS SP8 laser scanning microscope. Images were acquired with Volocity software 
(PerkinElmer). The asterisk indicates statistical significance (P < 0.05 by Student’s t test) vs. 
the control or another CAR construct.
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Fig. 3. IL-15 production and phenotype of iC9/CAR.19/IL15-transduced CB-NK cells
(A) IL-15 production by NT-NK cells or CAR transduced NK cells cultured in the presence 
or absence of CLL targets for 24h, 48h or 72hs in 4 independent experiments. For each time 
point, secretion of IL-15 by iC9/CAR.19/IL15-transduced CB NK cells was greater in the 
presence of antigenic stimulation in the form of CLL targets compared to iC9/CAR.19/IL15-
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transduced CB NK cells cultured alone (p<0.05 in all 3 cases). (B) CB-NK cell phenotype 
based on the average expression of 25 markers, including NK cell receptors, transcription 
factors, adaptor molecules, homing receptors and markers of exhaustion, in triplicate 
experiments. MFI or the percentages of positive cells were submitted to a hierarchical 
clustering program to generate a global view of marker expression in iC9/CAR.19/IL15-
transduced NK vs. non-transduced (NT) CB-NK cells (n=3 independent NK expansion and 
transduction experiments using different CB units). The transduced cells lacked any 
phenotypic evidence of exhaustion and maintained a phenotype similar to that of NT CB-
NK cells. (C) Proliferative capacity of CAR-transduced vs. NT CB-NK expansion in 
response to in vitro stimulation with clone 9 and IL-2 (200 iU/mL). The kinetics of iC9/
CAR.19/IL15 NK fold expansion in vitro was similar to NT-NKs (starting from 2 x106 CB-
NK cells; N=5).
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Fig. 4. In vivo homing, proliferation and antitumor activity of iC9/CAR.19/IL15-transduced CB-
NK cells in NSG Raji mouse model
(A) Bioluminescence imaging was used to monitor the growth of FFluc-labeled Raji tumor 
cells in NSG mice. The plot summarizes the bioluminescence data from 4 groups of mice 
treated with Raji alone, or Raji plus one dose (10 × 106) of iC9/CAR.19/IL15 CB-NK cells, 
CAR.19 (no IL-15) CB-NK cells or NT CB-NK cells (5 mice per group). Infusion of one 
dose of 10 × 106 iC9/CAR.19/IL15-transduced CB-NK cells into NSG mice engrafted with 
FFluc-labeled Raji cells results in superior control of tumor (blue line) compared with NT 
CB-NK cells (green line) and NK cells transduced with CAR.19 lacking IL-15 (pink line). 
(B) BLI figures of the experiments described in panel A. Colors indicate intensity of 
luminescence (red, highest; blue, lowest). (C) Kaplan Meier plots showing the probability of 
survival for the 4 groups of mice described in Panel A (5 mice per group). Mice treated with 
a single dose of 10 × 106 iC9/CAR.19/IL15-transduced CB NK cells (blue line) had 
significantly better survival than mice receiving CB-NK cells that were either not transduced 
(green line) (p=0.001) or transduced with a CAR.CD19 construct lacking IL-15 (pink line) 
(p=0.044). (D) Kaplan Meier plots showing that infusion of two doses (10 × 106 each, 5 – 7 
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days apart) of iC9/CAR.19/IL15-transduced CB-NK cells in NSG mice engrafted with Raji 
cells resulted in better survival, but was associated with early toxicity. P values were 
computed using the log rank test. (E) NSG mice were treated with Raji cells alone or Raji 
plus two doses (10 × 106 each, 5 – 7 days apart) of iC9/CAR.19/IL15 CB-NK cells, CAR.19 
(no IL-15) CB-NK cells or NT CB-NK cells (n=5 mice per group). Mice were sacrificed on 
day +21 post-infusion and peripheral blood, bone marrow (BM), liver and spleen were 
harvested and analyzed by flow cytometry for expression of human (h)CD45, hCD19, 
hCD56 and CAR. Representative FACS plots are presented. iC9/CAR.19/IL15 transduced 
CB-NK cells home to sites of disease (liver, spleen, BM) more efficiently than CAR.19 
transduced CB-NK cells or NT-NK cells and control disease. (F) Mice that received Raji 
cells plus two doses (10 × 106 each, 5 – 7 days apart) of iC9/CAR.19/IL15 CB-NK cells 
were monitored over time by weekly blood collection for expansion of CAR-expressing NK 
cells. Serial measurement of CAR expressing NK cells in the peripheral blood of mice by 
flow cytometry shows iC9/CAR.19/IL15+ CB-NK cells expand over time and could be 
detected up to 68 days post infusion.
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Fig. 5. IL-15-transduced CB-NK cells lack signs of autonomous or dysregulated growth
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(A) iC9/CAR.19/IL15-transduced CB NK and NT CB NK cells were put in culture without 
cytokines or exogenous stimulation to assess their growth over time. iC9/CAR.19/IL15-
transduced CB NK cells stop expanding within 6 weeks of in vitro culture with no evidence 
of autonomous growth. (B) NSG mice 10 months after treatment with CB-NK cells 
transduced with iC9/CAR.19/IL15 or CAR.19 (no IL15) were sacrificed and examined for 
evidence of NK dysregulated growth or leukemia/lymphoma. Photomicrographs of 
mesenteric lymph nodes show vestigial lymphoid tissue with no lymphocytic infiltration. 
Images of the spleen show rudimentary periarteriolar lymphoid tissue devoid of lymphocytes 
(black arrows) and is surrounded by hematopoietic tissue comprising of erythroid and 
myeloid series cells in different stages of development, including megakaryocytes and 
hemosiderin-laden macrophages. Bone marrow contains normal hematopoietic cells and no 
abnormal lymphocytes. H&E stain, magnification x200. The micrographs are from two 
representative groups of NSG mice treated with iC9/CAR.19/IL15-transduced CB-NK cells.
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Fig. 6. Activation of inducible caspase-9 suicide gene eliminates iC9/CAR.19/IL15+ CB-NK cells
(A) Addition of 10 nM of AP1903 to cultures of iC9-CAR-IL15+ CB-NK cells induced 
apoptosis/necrosis of transgenic cells within 4 hours as assessed by annexin-V-7AAD 
staining in 4 independent experiments. The dimerizer did not induce apoptosis in NT NK 
cells. (B) A representative FACS plot of the experiment described in Panel A is presented. 
(C) NSG mice engrafted with Raji cells and infused with iC9/CAR.19/IL15+ CB-NK cells 
were treated 10–14 days later with two doses of the AP1903 dimerizer (50 μg) i.p. 2 days 
apart. FACS plots from a representative experiment are presented. iC9/CAR.19/IL15-
expressing NK cells were substantially reduced in all organs tested 3 days later as measured 
by the frequencies of CAR-positive NK cells in blood, bone marrow, spleen and liver of 
animals by flow cytometry.
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